Mutant gene identified as villain in hardening of the arteriesDecember 19, 2007New Haven, Conn.-A genetic mutation expands lesions in the aorta and promotes coronary atherosclerosis, more commonly known as hardening of the arteries, according to a study by Yale School of Medicine in Cell Metabolism. The researchers found that mice engineered without the Akt1 gene and fed a high cholesterol diet had many more signs of aortic atherosclerosis compared to their littermates. And, surprisingly, their coronary lesions were similar to humans, say the scientists. "About 20 percent of the mice died spontaneously, perhaps due to an acute heart attack," said William Sessa, senior author of the study, professor of pharmacology, and director of Yale's vascular biology and therapeutics program. Atherosclerosis is a chronic inflammatory response in arterial walls, in large part due to deposits of lipoproteins-which are plasma proteins that carry cholesterol and triglycerides. The "hardening" or "furring" of the arteries is caused by plaque formation. In the vascular wall, Akt plays an important role in regulating the development of endothelial cells, which line the entire circulatory system, from the heart to the smallest capillary. Endothelial cells play an important role in regulating blood pressure, in blood clotting, in plaque formation in the arteries, and in formation of new blood vessels. "The major finding of this study is that an absence of Akt1 aggravates atherosclerotic lesions, promotes coronary atherosclerosis, and may be a model of acute coronary syndromes," Sessa said. "Specific activation of Akt1 may provide a therapeutic approach to decrease formation of lesions in the arterial wall and promote plaque stabilization to prevent an acute heart attack." One concern, he said, is that specific drugs are being developed to inhibit Akt in cancer patients to reduce progression of tumors, and that these drugs may also promote hardening of the arteries. Yale University |
|||||||||||||||||||||
| Related Coronary Atherosclerosis Current Events and Coronary Atherosclerosis News Articles Despite size, NFL players not more likely to develop heart disease, even after retirement Former professional football players with large bodies don't appear to have the same risk factors for heart disease as their non-athletic counterparts, UT Southwestern Medical Center researchers have found in studying a group of National Football League (NFL) alumni. Contraceptive use may be safe, but information gaps remain Introduced in the 1960s, oral contraceptives have been used by about 80 percent of women in the United States at some point in their lives. Drug may reduce coronary artery plaque Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque. Long-term HIV treatment may reduce risk for atherosclerosis Antiretroviral drugs for HIV do not increase the risk for coronary atherosclerosis, a central risk factor for heart disease, according to a study led by the University of Pittsburgh Graduate School of Public Health to be published in the Aug. 8 issue of the journal AIDS and available online today. Fat around the heart may increase risk of heart attacks When it comes to risk for a heart attack, having excess fat around the heart may be worse than having a high body mass index or a thick waist, according to researchers from Wake Forest University Baptist Medical Center and colleagues reporting in the August issue of the journal Obesity. Left main coronary artery disease can double or treble heart risk in siblings German researchers have found that heart disease of the left main coronary artery is often an inherited condition that clusters in families. Moreover, they discovered that initially healthy siblings of a person with the condition were 2.5 times more likely to go on to develop some form of heart disease than were siblings of a patient with heart disease that did not relate to the left main coronary artery. Despite significantly raising HDL, torcetrapib failed to slow the progression of coronary plaques Investigators reported today that torcetrapib, a drug that substantially raises high-density lipoprotein cholesterol or HDL (the "good" cholesterol), did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe (IVUS). Combination HDL/LDL therapy has no effect on plaque build-up For some patients with high cholesterol, even the most aggressive treatment with statin drugs fails to prevent coronary artery disease. Patients with hyperlipidemia - high LDL or "bad" cholesterol and trigylcerides, and low HDL or "good" cholesterol - and those with a family history of high cholesterol are at a high risk for atherosclerosis, or plaque build up in the coronary arteries, which can lead to a heart attack or stroke. Statin therapy associated with regression of coronary atherosclerosis with key lipid level changes An analysis of data from four clinical trials suggests that statin therapy is associated with regression of coronary atherosclerosis when low-density lipoprotein cholesterol (LDL-C or "bad" cholesterol) is substantially reduced and high-density lipoprotein cholesterol (HDL-C or "good" cholesterol) is increased, but it remains to be determined whether this degree of atherosclerosis regression will translate to meaningful reductions in cardiovascular events. Diabetes drug may reduce cardiovascular risks A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes. More Coronary Atherosclerosis Current Events and Coronary Atherosclerosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||